Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TRPM5 | Q9NZQ8 | 5/20 | 0.42 |
| ▸ | TRPM4 | Q8TD43 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507339 | 0.83 | GAA (0.49) | ALOX12GAAMAPTMEN1KMT2A | |
| SCHEMBL14509714 | 0.82 | ALOX12 (0.48) | ALOX12GAAMAPTTDP1TRPM5 | |
| SCHEMBL12197253 | 0.72 | ALOX12 (0.46) | ALOX12TRPM5TRPM4KDM1AMAOA | |
| SCHEMBL14510179 | 0.71 | LMNA (0.41) | ALOX12GAAMEN1KMT2ACYP3A4 | |
| SCHEMBL5508284 | 0.71 | GAA (0.51) | ALOX12GAAMAPTTDP1MEN1 | |
| SCHEMBL14509981 | 0.69 | ALOX12 (0.43) | ALOX12GAAMAPTTDP1TRPM5 | |
| SCHEMBL18585775 | 0.69 | CYP3A4 (0.66) | GAAMAPTTDP1KIF11MEN1 | |
| SCHEMBL11547755 | 0.68 | ALOX12 (0.43) | ALOX12GAAMAPTTRPM5TRPM4 | |
| SCHEMBL17087389 | 0.68 | TRPM5 (0.35) | TRPM5TRPM4 | |
| SCHEMBL11047272 | 0.66 | HTR5A (0.41) | ALOX12GAAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1047676-B1 | SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION | HARVARD COLLEGE (US) | 2007-06-27 | — | — | EP | disclosed |
| US-6992079-B2 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | President Fellows of Harvard College (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040002486-A1 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-01-01 | — | — | US | disclosed |
| US-20030191111-A1 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | CHILDREN'S MEDICAL CENTER CORPORATION | 2003-10-09 | — | — | US | disclosed |
| US-20030134842-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION | BRUGNARA CARLO (US) | 2003-07-17 | — | — | US | disclosed |
| US-6534497-B1 | Specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by | NUCHEM PHARMACEUTICALS, INC. (CA) | 2003-03-18 | — | — | US | disclosed |
| US-6291449-B1 | Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours | CHILDREN'S MEDICAL CENTER CORPORATION | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002486-A1 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | MKI67, BOD1L1, BRCA1 | ALOX12 1742/4885GAA 650/4885MAPT 4135/4885 |
| US-20030191111-A1 | Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation | MKI67, BOD1L1, BRCA1 | ALOX12 1742/4885GAA 650/4885MAPT 4135/4885 |
| US-20030134842-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION | KCNN2, KCNN1, KCNN3 | ALOX12 136/4885GAA 415/4885MAPT 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.